摘要
目的:观察PD-1单抗治疗晚期肿瘤的临床疗效及安全性。方法:回顾性分析PD-1单抗治疗48例晚期肿瘤患者的临床效果,评价其客观有效率、无疾病进展生存期、总生存期及不良反应。结果:48例患者在接受PD-1单抗2周期治疗后,完全缓解(CR)0例,部分缓解(PR)3例,疾病稳定(SD)33例,疾病进展(PD)12例,客观有效率(ORR)为6.25%,疾病控制率(DCR)为75%。截至随访结束,33例出现无进展生存期(PFS)终点事件,12例出现总生存期(OS)终点事件,全组客观有效率(ORR)为6.25%,疾病控制率(DCR)为75%,中位PFS为106.5天,中位OS为185天。肺癌亚组客观有效率(ORR)为4.55%,疾病控制率(DCR)为81.8%,中位PFS为106.5天,中位OS为202天。全组不良反应发生率为31.2%,主要为恶心呕吐7例(14.5%),骨髓抑制5例(10.4%),发热2例(4.2%),皮疹1例(2.1%),肝功能损害2例(4.2%)。结论:PD-1单抗治疗晚期肿瘤具有一定疗效,患者耐受性良好。
Objective： To observe the clinical effect and toxicity of anti- PD- 1 antibody in 48 patients with advanced cancer. Methods： Forty- eight patients with advanced cancer were retrospectively analyzed. Nivolumab / Pembrolizumab was venoclysis taken by patients,to evaluate the short- term response,progression free survival（ PFS）,overall survival（ OS） and toxicity. Results： After two cycles treatment,among the 48 patients,no cases experienced complete response（ CR）,3 cases experienced partial response（ PR）,33 cases were with stable diseases（ SD）,12 cases were with progression disease（ PD）. At the end of the follow- up period,thirty- three cases had PD and twelve cases died. The tumor objective response rate（ ORR） and disease control rate（ DCR） were 6. 25% and 75% respectively,the median PFS was 106. 5 days and median OS was 185 days. Subgroup analysis of lung cancer： The ORR was4. 55% and DCR was 81. 8%,the median PFS was 106. 5 days and median OS was 202 days. Among the 48 cases,the incidence of side effects was 31. 2%,including the digestive tract reaction（ 14. 5%）,bone marrow suppression（ 10. 4%）,fever（ 4. 2%）,rash（ 2. 1%）,and mildimpair of liver function（ 4. 2%）. Conclusion： Anti- PD- 1 antibody is effective with high drug tolerance for advanced cancer.
作者
夏媛媛
张国庆
胡毅
Xia Yuanyuan Zhang Guoqing Hu Yi(Department of Medical Oncology, Chinese PLA General Hospital, Beifing 100853, China.)
出处
《现代肿瘤医学》
CAS
2016年第23期3783-3786,共4页
Journal of Modern Oncology
基金
北京市自然科学基金(编号:7162179)
